Background: PTEN is a tumor suppressor frequently deleted in prostate cancer that may be a useful prognostic biomarker. However, the association of PTEN loss with lethal disease has not been tested in a large, predominantly surgically treated cohort.
Methods

Study Population
We included 1044 men diagnosed with prostate cancer who were participants in the PHS (n = 245) (32, 33) or HPFS (n = 799) (34) . The men were diagnosed with cancer between 1983 and 2009 and had available archival prostate tumor materials for evaluation. The PHS was a randomized trial investigating the prevention of cardiovascular disease and cancer among 29 071 male physicians aged followed with annual questionnaires since 1982. The HPFS is an ongoing cohort of 51 529 male health professionals followed with biannual questionnaires since 1986. Incident prostate cancers (ICD-9: 185) were self-reported and confirmed through medical record and pathology report review. Details of the prostate cancer tumor cohorts within these two studies are available elsewhere (23) .
Clinical and Follow-up Data
We abstracted data on tumor stage, prostate specific antigen (PSA) level at diagnosis, and treatments from medical records and pathology reports. Standardized histopathologic review by study pathologists of H&E slides of each case provided uniform Gleason grading (35) . Prostate cancer patients were followed up with written questionnaires to collect detailed information regarding treatments and clinical progression. Biochemical recurrence was reported by participants, the treating physician, or abstracted from medical records, defined as a PSA above 0.2 ng/mL postsurgery sustained over two measures. The date of first increase in PSA was considered the date of biochemical recurrence. For prostate cancer cases in the HPFS, treating physicians were contacted to collect clinical course information and to confirm development of metastases. For prostate cancer cases in the PHS, 80% of reports of metastases were confirmed by medical record review; we thus relied on self-report because available records corroborated the self-report of these physician participants in virtually every instance. Cause of death was determined by medical record and death certificate review. Follow-up for mortality in the cohorts is greater than 98%.
Immunohistochemical Assessment of Protein Expression
We characterized TMPRSS2:ERG fusion status and PTEN expression on tumor tissue available from a biorepository of archival radical prostatectomy (RP; 95%) and transurethral resection of the prostate (TURP; 5%) tumor specimens. Hematoxylin and eosin slides were reviewed by our study pathologists (MF, SF) to confirm prostate cancer and to identify tumor areas for tissue microarray (TMA) construction. Thirteen TMAs were constructed by sampling at least three 0.6 mm cores of tumor per case from the dominant nodule or nodule with the highest Gleason pattern. A detailed description of the immunohistochemical methods is provided in the Supplementary Methods (available online) and previous studies (6, 36) . Briefly, PTEN IHC was performed using a rabbit antihuman PTEN antibody (Clone D4.3 XP; Cell Signaling Technologies, Danvers, MA), which has been shown to strongly correlate with FISH and high-resolution single-nucleotide polymorphism (SNP) array analysis (6) . PTEN scoring was conducted by study pathologists (TLM and CLM) who were both blinded to clinical and outcome data. A tissue core was considered to have PTEN protein loss if the intensity of cytoplasmic and nuclear staining was markedly decreased or entirely lost (0+ intensity) or markedly decreased (1+ intensity) across more than 10% of tumor cells compared with surrounding benign glands and/or stroma, which provide internal positive controls for PTEN protein expression (Figure 1 ). This simple dichotomous scoring system has been shown to be strongly associated with underlying homozygous genetic deletion of PTEN in prior studies by SNP array and fluorescence in situ hybridization (6) and showed high interobserver reproducibility in the tumor samples from the current study (Supplementary Methods, available online). We previously performed ERG IHC on a subset of tumors (Clone EPR3864, Epitomics, Inc., Burlingame, CA) (22) , which is strongly associated with fusion status assessed by FISH (36) . We classified tumors as ERG positive (ie, carrying the TMPRSS2:ERG T. U. Ahearn et al. | 3 of 9 article gene fusion) if at least one core stained positive for ERG and ERG negative if all cores stained negative for ERG.
Statistical Methods
We compared demographic, clinical characteristics, and prognostic outcomes according to PTEN expression. We used Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of the association between PTEN loss with time to development of lethal prostate cancer (defined as prostate cancer death or metastases to bone or other organ) and PSA recurrence. Person-time was calculated from the date of cancer diagnosis to the earliest of the following time points: either development of lethal prostate cancer or PSA recurrence (depending on the endpoint for the analysis), censored at time of death from other causes, or end of follow-up (March 2011 for the PHS and December 2011 for the HPFS). We adjusted for age at diagnosis (years, continuous) and BMI at diagnosis (kg/m 
Results
The association between PTEN loss and lethal progression did not statistically differ between the two cohorts; we therefore present results for the combined cohorts. Of the 1044 cases with characterized PTEN expression, 16% had complete PTEN loss in all TMA cores, 9% had heterogeneous PTEN loss across cores, and 75% had intact PTEN expression in all cores. Selected clinical and demographic characteristics of the cohort are presented in Table 1 . Tumors with complete PTEN loss were statistically significantly more likely to be ERG positive and to have a higher Gleason grade and more advanced clinical and pathologic tumor stage. Moreover, complete PTEN loss tended to be associated with a lower mean BMI at diagnosis, though this was not a statistically significant finding. The frequency of PTEN loss was similar among the RP and TURP specimens. No appreciable association was seen between PTEN expression and age at diagnosis, PSA at diagnosis, or with having a family history of prostate cancer.
During a mean follow-up time of 11.7 years, there were 81 (HPFS n = 59 and PHS n = 22) lethal prostate cancer events. Men whose tumors showed complete PTEN loss had a statistically significantly higher risk for lethal progression compared with men whose tumors showed PTEN intact or heterogeneous loss, even after adjusting for clinical-pathologic characteristics (HR = 1.8, 95% CI = 1.2 to 2.9). Similar results were found when comparing tumors with any PTEN loss (heterogeneous or complete) to intact PTEN. However, complete PTEN loss (HR = 1.9, 95% CI = 1.2 to 3.0), but not heterogeneous PTEN loss (HR = 1.2, 95% CI = 0.5 to 2.6), was associated with lethal progression after adjustment for clinical-pathologic characteristics (Table 2) . Similar results were found when prostate cancer-specific death was used as the outcome (data not shown).
The association of complete PTEN loss with lethal progression did not statistically differ according to subgroups of clinical characteristics or by tissue specimen. There was a suggestion that PTEN loss may be more associated with lethal progression in advanced pathologic stage tumors (HR = 2.1, 95% CI = 1.1 to 3.9), compared with nonadvanced pathologic stage tumors (HR = 0.7, article 95% CI = 0.2 to 2.5), but this was not a statistically significant difference and based on only three lethal events in the nonadvanced group (Table 3) . Complete PTEN loss was associated with lethal progression in tumors diagnosed in both the pre-PSA and PSA eras (data not shown). Restricting analyses to cases who had a minimum of three TMA cores scored for PTEN expression did not appreciably alter our findings (data not shown).
Complete PTEN loss was associated with a higher risk for PSA recurrence in the minimally adjusted model but was attenuated and no longer statistically significant following adjustment for clinical parameters (data not shown).
The association of PTEN loss stratified by ERG expression with lethal progression is presented in Figure 2 and Table 4 .
Compared with ERG-negative cases with intact PTEN, ERGnegative cases with any PTEN loss (complete or heterogeneous) had a statistically higher risk for lethal progression, even after adjustment for Gleason grade and clinical stage (HR = 3.1, 95% CI = 1.7 to 5.7. In contrast, ERG-positive cases with (HR = 1.2, 95% CI = 0.7 to 2.2) or without (HR = 1.0, 95% CI = 0.5 to 1.9) PTEN loss were not at higher risk of lethal progression (P interaction = .05). In a subset of cases with pathologic stage data available, adjusting for pathologic TNM did not appreciably alter these results (P interaction = .02) ( Table 4) . Results were similar when PTEN loss was classified as PTEN loss in all cores and as PTEN intact for any cores with PTEN expression (Table 5) . 
article
Discussion
In this large patho-epidemiology investigation, we found that PTEN loss, as assessed by a validated and simple IHC protocol, was associated with a two-fold increase in risk of lethal progression independent of clinical-pathologic parameters. PTEN loss was heterogeneous in about one-third of cases that showed any loss; however, the association with lethal disease was restricted to the men with prostate cancer showing complete loss of PTEN in all sampled tumor glands. PTEN loss (either heterogeneous or complete) was associated with lethal progression primarily among ERG-negative cases and this association was seen after adjustment for pathologic grade and stage. In contrast, PTEN loss among ERG-positive tumors was not associated with lethal progression. To the best of our knowledge, this is the first study to relate combined PTEN and ERG expression to lethal progression in a predominantly surgically treated cohort. Our findings may have important implications for improving our understanding of biologic pathways that drive prostate cancer progression. Moreover, these results suggest that characterizing tumor PTEN and ERG status via simple and relatively inexpensive IHC assays may have clinical utility for distinguishing distinct molecular subtypes of prostate cancer, improving disease risk stratification, and potentially helping to guide treatment decisions. Most previous studies investigating the prognostic role of PTEN have used biochemical recurrence as the primary outcome, with the majority finding that loss is associated with an increased risk of biochemical recurrence (7,9,11,37-39), but results are not entirely consistent (8, 31, 40) . A limitation of using biochemical recurrence as an outcome is that only a small subset of cases who experience biochemical recurrence will die of prostate cancer (41) . Though lethal progression is a more informative endpoint, only a few studies have been able to relate PTEN loss with lethal progression. In the HPFS and PHS, we previously reported that reduced PTEN expression, assessed by a different IHC antibody than that used in the current study (Zymed cat# 18-0256), was associated with an increased risk of lethal progression (HR = 2.4, 95% CI = 1.2 to 4.7). However, following adjustment for clinical characteristics, the association was no longer statistically significant (42) . In another study of 675 conservatively managed cases diagnosed by TURP, 18% of cases had PTEN loss by IHC using a similar assay to ours. PTEN loss was associated with a 1.5-fold increased risk of prostate cancer death following adjustment for Gleason grade and PSA (43) . Finally, among 217 high-risk surgically treated cases who experienced biochemical recurrence following RP, PTEN loss assessed by our assay was statistically significantly associated with increased risk of metastatic progression (6), though this association did not remain significant after adjusting for grade and stage.
We show that the association of PTEN loss with lethal outcomes was strongest among ERG-negative tumors. Few studies have investigated concomitant PTEN and ERG status in relation to disease progression. Similar to earlier reports, we found PTEN loss was substantially enriched for ERG expression (71%) compared with PTEN-positive tumors (46%) (10, (24) (25) (26) . Perhaps explaining this tendency towards co-occurrence, mouse models have suggested that PTEN loss and TMPRSS2:ERG are incapable of driving prostate tumor growth alone, but together these molecular alterations synergize, driving cell migration and invasion (13) . Supporting this finding, Yoshimoto et al. (37) and Leinonen et al. (39) found the highest risk for biochemical recurrence was among fusion-positive tumors with PTEN loss. However, a much larger study by Krohn et al. did not find that tumor fusion status modifies the association of PTEN loss with biochemical recurrence (10) . Prior to our study, only Reid et al. had related PTEN and ERG status to lethal progression in a conservatively managed TURP cohort. Despite important cohort differences, Reid et al. also found the highest risk for lethal progression among cases with PTEN loss and negative fusion status (HR = 4.9, 95% CI = 2.3 to 10.4) (31), but this group did not replicate this finding in a larger study (43) .
Recently, Chen et al. reported on a transgenic mouse model of TMPRSS2:ERG and PTEN loss in which androgen receptor signaling was downregulated in PTEN-negative and fusion-negative tumors (44) . These findings present a potential explanation for our findings, in that further repressing androgen signaling in these tumors may be an ineffective treatment strategy. Indeed, Mulholland et al. demonstrated better inhibition of in vitro growth of PTEN-null tumors when AR/androgen blockage was combined with PI3K/Akt/mTOR inhibition (15) . However, Chen et al. also found that ERG expression restored androgen signaling among PTEN-null tumors, enabling development of invasive prostate cancer, suggesting PTEN loss and ERG expression cooperate to promote tumor growth (44) . Thus, additional research is needed to validate our finding and to clarify how the interplay between PTEN loss and TMPRSS2:ERG fusion affects disease progression.
This study benefits from a large sample size, long follow-up, and prospectively monitored and validated prostate cancer outcomes. Our study pathologists reviewed and provided uniform Gleason grades for all cases reducing measurement error. We used cause-specific death and distant metastasis as the outcome, which are the most clinically relevant endpoints for prostate cancer. The PTEN IHC assay has been validated and is strongly associated with the presence of underlying PTEN gene deletions (6) . However, this study does have limitations. We had a limited number of lethal events, especially limiting our statistical power in our subgroup analyses; therefore, these results should be interpreted cautiously. We mainly used prostatectomy tissue in this investigation; therefore our results may not be generalizable to biopsy specimens. However, a recent investigation using the same PTEN assay among active surveillance-eligible case patients found PTEN loss was associated with an increased risk of upgrading at radical prostatectomy (20) . Because our study utilized TMAs, tumor heterogeneity is also likely to be an important limitation, article as some cases with heterogeneous PTEN loss may have been missed because of tumor sampling, but this would likely attenuate our findings. Importantly, the association of PTEN loss with lethal events among ERG fusion-negative tumors was much stronger than that seen for PTEN loss considered without ERG status, and this association remained strong even when considering tumors with heterogeneous PTEN loss. Finally, white men primarily comprise our cohort (97%), so our results may not be generalizable to other racial/ethnic groups, in which ERG expression and PTEN loss may be less frequent (45) (46) (47) (48) (49) (50) .
In conclusion, PTEN loss is associated with an increased risk of lethal progression in prostatectomy samples independent of clinical parameters. When considered alone, complete PTEN loss, but not heterogeneous loss, is associated with lethal progression. When considered with ERG, any PTEN loss was associated with lethal progression in ERG-negative cases but not in ERG positive cases. Importantly, both the PTEN and ERG IHC assays are simple to interpret with dichotomous scoring systems, relatively inexpensive compared with DNA-based assays, and currently running on automated platforms in our CLIA-certified pathology laboratory. These findings support the continued development of PTEN and ERG as prognostic biomarkers and, if replicated in large biopsy cohorts, may have important clinical implications for risk stratification and identifying cases likely to benefit from therapies targeting the PI3K/Akt signaling pathway.
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